PhaseBio Pharmaceuticals Debt/Equity

Debt/Equity of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.


Highlights and Quick Summary

  • Debt/Equity for the quarter ending June 29, 2021 was -0.59 (a -138.84% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -116.38%
  • Annual Debt/Equity for 2020 was -0.56 (a -304.19% decrease from previous year)
  • Annual Debt/Equity for 2019 was 0.27 (a 86.49% increase from previous year)
  • Annual Debt/Equity for 2018 was 0.15 (a -107.4% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of PhaseBio Pharmaceuticals

Most recent Debt/Equityof PHAS including historical data for past 10 years.

Interactive Chart of Debt/Equity of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.59 1.51
2020 -0.56 3.58 0.64 0.28 -0.56
2019 0.25 0.14 0.12 0.16 0.27
2018 0.15 0.79 0.0 0.0 0.15
2017 0.0 -1.99
2016 0.0

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.